ASTRAZENECA INVITES YOU TO ATTEND

Saphnelo® (anifrolumab-fnia)
Intravenous Use 300 mg/vial

An Overview of Systemic Lupus Erythematosus (SLE) Disease Burden, Assessment, and Treatment

PRESENTED BY:
Alan Epstein, M.D.

JOIN US:
La Belle Helene Restaurant
300 South Tryon Street
Charlotte, NC 28202

March 9, 2024
07:00 PM – 09:00 PM
Eastern Standard Time

RSVP:
Veena Ramnath
(914) 380-0973 veena.ramnath@astrazeneca.com
BY: 3/6/2024

INDICATION

SAPHNELO is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.

Limitations of Use: The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use is not recommended in these situations.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

Known history of anaphylaxis with SAPHNELO.

WARNINGS AND PRECAUTIONS

- **Serious Infections:** Serious and sometimes fatal infections have occurred in patients receiving immunosuppressive agents, including SAPHNELO. SAPHNELO increases the risk of respiratory infections and herpes zoster. Use caution in patients with severe or chronic infections. Avoid initiating treatment during an active infection and consider interrupting therapy in patients who develop a new infection during treatment
- **Hypersensitivity Reaction Including Anaphylaxis:** Serious hypersensitivity reactions (including anaphylaxis) have been reported following SAPHNELO administration. Events of angioedema have also been reported. Other hypersensitivity reactions and infusion-related reactions have occurred following administration of SAPHNELO. SAPHNELO should be administered by healthcare providers prepared to manage hypersensitivity reactions, including anaphylaxis and infusion-related reactions, if they occur. Immediately interrupt administration and initiate appropriate therapy if a serious infusion-related or hypersensitivity reaction (eg, anaphylaxis) occurs
- **Malignancy:** There is an increased risk of malignancies with the use of immunosuppressants. The impact of SAPHNELO on the potential development of malignancies is not known
- **Immunization:** Avoid the use of live or live-attenuated vaccines in patients treated with SAPHNELO
- **Use With Biologic Therapies:** SAPHNELO is not recommended for use in combination with other biologic therapies, including B-cell targeted therapies

See additional Important Safety Information on the reverse side.
Please see accompanying full Prescribing Information, including Patient Information for SAPHNELO.

AstraZeneca

This program is intended for US healthcare professionals only.
AstraZeneca will comply with any and all federal or state reporting requirements regarding any value or expense associated with this event. AstraZeneca fully supports and abides by the PhRMA Code on Interactions With Healthcare Professionals (HCPs). This program is open only to HCP invitees. AstraZeneca will not accommodate attendance of a spouse or other guest of any HCP attendee, nor will AstraZeneca pay for transportation or parking costs of attendees. If you are a prescriber and/or a Federal, State, or institution employee, you may be subject to laws, regulations, or rules that prohibit or limit your receipt of gifts, meals, or items of value. We ask that you comply with any such restrictions. This is a presentation sponsored directly by AstraZeneca and there are no continuing medical education (CME), continuing nursing education (CNE), or continuing education (CE) credits associated with this activity. AstraZeneca will not recommend, endorse, or support the submission of this promotional program for CE credits.

IMPORTANT SAFETY INFORMATION (continued)

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5%) are nasopharyngitis, upper respiratory tract infections, bronchitis, infusion-related reactions, herpes zoster and cough.

In the controlled clinical trials, the incidence of infusion-related reactions was 9.4% in patients while on treatment with SAPHNELO and 7.1% in patients on placebo. Infusion-related reactions were mild to moderate in intensity; the most common symptoms were headache, nausea, vomiting, fatigue, and dizziness.

USE IN SPECIFIC POPULATIONS

Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to SAPHNELO during pregnancy. For more information about the registry or to report a pregnancy while on SAPHNELO, contact AstraZeneca at 1-877-693-9268.

There are insufficient data on the use of SAPHNELO in pregnant women to establish whether there is drug-associated risk for major birth defects or miscarriage. Advise female patients to inform their healthcare provider if they intend to become pregnant during therapy, suspect they are pregnant or become pregnant while receiving SAPHNELO.

Lactation: No data are available regarding the presence of SAPHNELO in human milk, the effects on the breastfed child, or the effects on milk production.

Pediatric Use: The safety and efficacy of SAPHNELO in pediatric patients less than 18 years of age has not been established.

Please see accompanying full Prescribing Information, including Patient Information or scan here.

You are encouraged to report negative side effects of AstraZeneca prescription drugs by calling 1-800-236-9933. If you prefer to report these to the FDA, call 1-800-FDA-1088.

Saphnelo®
(anifrolumab-fnia)
Intravenous Use 300 mg/vial

AstraZeneca